



Select Investment Series III SICAV T.Rowe Price Health Sciences Equity Fund Class Q / LU2349435961 / A3C5BC /

| Last 10/31/2024 ¹ | Region | | Branch | | | Type of yield | Туре | |
|------------------------------|---|----------|------------------------|---------|--|--|----------------|----------------------------------|
| 9.48 USD | Worldwide | | Sector Health / Pharma | | | reinvestment | Equity Fund | d L |
| ■ Benchmark: IX Aktien Gesun | SICAV T.Rowel price Haalth Sciences dheit/Pharris | s Equity | | 2024 | 30.0% 27.5% 25.0% 22.5% 20.0% 17.5% 15.0% 12.5% 10.0% 7.5% 5.0% 2.5% -2.5% -5.0% -7.5% 10.0% -1.5% -1.0% -1.5% -1.0% -1.5% | Risk key figures SRI 1 Mountain-View Fund A A A A Yearly Performa 2023 | Δ | 5 6 7 EDA ³ 78 +4.93% |
| Master data | | | Conditions | | | Other figures | | |
| Fund type | Single f | fund l | Issue surcharge | | 0.00% | Minimum investment | t | USD 1,000.00 |
| Category | Ec | quity | Planned administr. fee | | 0.00% | Savings plan | | - |
| Sub category | Sector Health / Pha | ırma l | Deposit fees | | 0.02% | UCITS / OGAW | | Yes |
| Fund domicile | Luxembo | ourg l | Redemption charge | | 0.00% | Performance fee | | 0.00% |
| Tranch volume | (10/31/2024) USD 53.48 | mill. | Ongoing charges | | - | Redeployment fee | | 0.00% |
| Total volume | (10/31/2024) USD 267.61 | mill. | Dividends | | | Investment comp | oany | |
| Launch date | 11/8/2 | 2021 | | | | | T.Rowe | Price M. (LU) |
| KESt report funds | | No | | | | 100 East Pratt | Street, MD 212 | 202, Baltimore |
| Business year start | 01 | .01. | | | | | United Sta | tes of America |
| Sustainability type | | | | | | | https://www.ti | oweprice.com |
| Fund manager | T. Rowe Price Internationa | | | | | | | |
| Performance | 1M | 61\ | | 1Y | | 2Y 3Y | 5Y | Since start |
| Performance | -4.05% | +6.16% | % +8.72% | +24.57% | +15.0 | 5% - | - | +17.91% |
| Performance p.a. | - | | | +24.50% | +7.2 | 5% - | - | +6.78% |
| Sharpe ratio | -4.71 | 0.7 | 7 0.59 | 1.61 | 0 | .31 - | - | 0.22 |
| Volatility | 8.82% | 12.40% | % 12.75% | 13.40% | 13.6 | 1% 0.00% | 0.00% | 17.19% |
| Worst month | - | -5.20% | % -5.20% | -5.47% | -5.4 | 7% -6.04% | 0.00% | -6.04% |
| Best month | - | 4.89% | % 8.32% | 8.32% | 8.3 | 2% 8.32% | 0.00% | 8.32% |
| Maximum loss | -4.63% | -6.60% | % -8.03% | -8.03% | -13.5 | 3% 0.00% | 0.00% | - |

Austria, Germany, Switzerland, Luxembourg, Czech Republic


¹ Important note on update status: The displayed date refers exclusively to the calculation of the NAV.
2 The Mountain-View Data Fund Rating calculates a computative ranking for funds using yield, volatility and trend data. For more information visit MVD Funds Rating
3 Displays the Ethical-Dynamical Ratio calculated according to standard criteria. The maximum value is 100. For more information visit EDA






Select Investment Series III SICAV T.Rowe Price Health Sciences Equity Fund Class Q / LU2349435961 / A3C5BC /

Assessment Structure



40


Largest positions



Countries Branches Currencies



20



100

